SPACs vs. traditional IPO's; Nasdaq Private Markets; Financings and Weekly Market Updates
LTSE Debut; Hedge Fund Launch Surge; Core Principles for Biotech Board Meetings; Market Update
FDA approvals for SternIR clients; new FDA draft guidance; SEC rulemaking; weekly market update
Muted Biotech Sentiment Heading into June?; Nasdaq: Now Accepting Primary Direct Floor Listings; “SPAC King” Funds 4 Biotech; Market and Client Weekly Updates
Trends in early stage financing rounds; Millennials and the proxy vote; Abingworth’s Most Recent Raise; Market update
Defining “The Good Crossover” Financing; GameStop Blowback; A New Index in Town?; Market Updates
1Q financing roundup; Rapid expansion of the biotech sector; Market update
Increasing SEC Enforcement Focus on SPACs; Gender Diversity in Company Creation; Weekly Market Update
Predicting the Future: Cowen Analyzes Biotech Performance in Higher Interest Rate Environments; FTC Crackdown on Pharma Mergers; Biotech Capital Flow and Market Updates
Congratulations to SternIR clients on recent NDA acceptances; recent SEC crackdowns; Cowen: The latest player in ESG; Investor Relations is a competitive advantage.
Top Biotech CEOs of 2021; This week in ESG; Biopharma Venture Investing Boom
The drumbeat for ESG initiatives is only growing louder.
Our take on the short squeeze, VC funding, and biotech financing
Preparing for Proxy Season; Planning for Virtual Annual Meetings; Market Update
BioCentury’s Look Ahead to 2021; Another Alternative to IPOs?; Vanguard and ESG
SternIR's look back on 2020.
Schedule a virtual 1x1 meeting with 75+ of our top-tier companies during the week of the Virtual J.P. Morgan Healthcare Conference, to be held on January 11 – 14, 2021.
Despite the holiday “break,” it’s been a very busy few weeks for Stern IR clients and we wanted to congratulate several on recent clinical, regulatory and corporate successes:
We hope you are all looking forward to some well-earned R&R over the Thanksgiving holiday – it’s been a wild few weeks for biotech!
Stern Investor Relations parent company, Precision Medicine Group, announced that it has completed a major investment and recapitalization led by funds managed by Blackstone, with significant participation from Precision’s co-founders, as well as current shareholders Berkshire Partners, TPG Growth, Oak HC/FT and Vida Ventures.
Let us begin by congratulating Stern IR client Gilead, who ranked highly in this year’s II awards across several metrics, including best investor relations program, best CEO and CFO, and best communication of strategy and risk management amid COVID-19. Go GILD!
We want to start by congratulating several Stern IR clients on major accomplishments, all from this week alone! We also have a 13F update, even more SPACs, and a market update.
#JPMorgan2021 – It’s Here!
Congratulating Stern IR clients, Atea Pharmaceuticals and Goldfinch Bio, who were named among Fierce Biotech’s 2020 Fierce 15, and Tmunity Therapeutics, who was named to the Endpoints 11!
Back to school and back to business, NASDAQ responds to the SEC’s proposed amendments to the 13F reporting threshold, and a market update.